Mirum (MIRM) SVP Jolanda Howe sells 842 shares after RSU vesting

Rhea-AI Filing Summary

Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity transactions. On January 23, 2026, 1,500 restricted stock units vested and converted into 1,500 shares of common stock at an exercise price of $0, increasing her directly held common stock to 4,542 shares.

On January 26, 2026, Howe sold 842 shares of Mirum common stock at $96.192 per share to cover tax withholding obligations tied to the RSU vesting. After these transactions, she directly owned 3,700 shares of common stock and 1,500 restricted stock units, which continue to vest in thirds annually from January 23, 2024.

Insider Trade Summary

Net Seller: 842 shares ($80,994)

Net Sell 3 txns

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 842 shs ($81K)

Type	Security	Shares	Price	Value
Sale	Common Stock	842	$96.192	$81K
Exercise	Restricted Stock Units	1,500	$0.00	--
Exercise	Common Stock	1,500	$0.00	--

Holdings After Transaction: Common Stock — 3,700 shares (Direct); Restricted Stock Units — 1,500 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		M		1,500	A	(1)	4,542	D
Common Stock	01/26/2026		S(2)		842	D	$96.192	3,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/23/2026		M			1,500	(3)	(3)	Common Stock	1,500	$0	1,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mirum (MIRM) SVP Jolanda Howe report?

Jolanda Howe reported RSU vesting and a related share sale. 1,500 restricted stock units converted into common shares, and 842 shares were sold at $96.192 each to cover tax withholding obligations. Following these transactions, she directly held 3,700 common shares and 1,500 restricted stock units.

How many Mirum (MIRM) shares did Jolanda Howe sell and at what price?

Jolanda Howe sold 842 shares of Mirum common stock at $96.192 per share. The sale was disclosed as covering tax withholding obligations from restricted stock unit vesting, rather than an open-market discretionary sale, and left her with 3,700 directly held Mirum common shares afterward.

What restricted stock unit activity did Mirum (MIRM) disclose for Jolanda Howe?

1,500 restricted stock units held by Jolanda Howe vested and converted into 1,500 shares of Mirum common stock at a $0 exercise price. These RSUs vest in three equal annual installments starting January 23, 2024, meaning the full award vests by the third anniversary of that date.

How many Mirum (MIRM) shares does Jolanda Howe own after the Form 4 transactions?

After the reported transactions, Jolanda Howe directly owns 3,700 shares of Mirum common stock and 1,500 restricted stock units. The balance reflects 1,500 RSUs vesting into shares and 842 shares sold to satisfy tax withholding tied to that vesting event, as disclosed.

Why did Jolanda Howe sell Mirum (MIRM) shares according to the Form 4?

The Form 4 states the 842 shares sold by Jolanda Howe were used to cover tax withholding obligations from the vesting of restricted stock units. This type of sale is a common administrative transaction made at vesting, rather than a separate discretionary stock sale decision.

What is the vesting schedule for Jolanda Howe’s Mirum (MIRM) restricted stock units?

The restricted stock units vest over three years. One-third of the RSUs vests on each anniversary of January 23, 2024, identified as the Vesting Commencement Date. By the third anniversary of that date, the entire RSU award is scheduled to be fully vested under the terms disclosed.